Surgical Oncology
Assistant Professor of Medical Oncology, Johns Hopkins University, USA.
Eric Christenson is an Assistant Professor of Medical Oncology at Johns Hopkins with a strong clinical and research focus on improving the care of patients with colorectal and pancreatic cancer. He is an active participant in the colorectal cancer tumor board and rectal cancer multidisciplinary clinic. Dr. Christenson is involved in clinical and pre-clinical investigations to credential novel treatment strategies, with an emphasis on combining targeted and immunotherapy approaches to improve outcomes for patients with GI malignancies.
Selected publications from PubMed
Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.
Christenson ES, Wala JA, Parkinson R, Collins NB, Jakubowski C, Lin JR, Qian K, Lu J, Wang H, Ho WJ, Chan S, Kulikowicz E, Klein R, Cetasaan Y, Johnson E, Berg M, Meyerhardt JA, Le DT, Schlechter BL, Browner I, Zheng L, Singh H, Donehower R, Jaffee EM, Sorger PK, Giannakis M, Azad N
Nat Commun. 2026 Jul 23;17(1) doi: 10.1038/s41467-026-72985-6.
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.
Wang HH, Huff AL, Haldar SD, Berg M, Thoburn C, Heumann TR, Anders RA, Barrett B, Bever KM, Pishvaian MJ, Lee V, Le DT, Christenson ES, Baretti M, Yarchoan M, Laheru D, Thomas A, Durham JN, Nauroth JM, Lu J, Wang H, Jaffee EM, Azad NS, Zaidi N
Nat Commun. 2026 Jun 23;17(1) doi: 10.1038/s41467-026-74711-8.
Total Neoadjuvant Treatment: A Dynamite Approach in the Treatment of Locally Advanced Rectal Cancer.
Winters HD, Meyer J, Christenson ES
JCO Oncol Pract. 2026 Jun;22(6):898-900 doi: 10.1200/OP-25-01031.
Considerations of Wait Intervals and Neoadjuvant Windows in Rectal Cancer.
Winters HD, Meyer J, Christenson ES
JCO Oncol Pract. 2026 May 20;:OP2600379 doi: 10.1200/OP-26-00379.
Sacral Fractures After Short-Course Radiation Therapy for Rectal Cancer.
Papanikolaou PA, Liu IC, Christenson ES, Kacker S, Narang AK, Meyer JJ
Adv Radiat Oncol. 2026 May;11(5):102030 doi: 10.1016/j.adro.2026.102030.
Dr. Christenson examines the current landscape of immunotherapy in mismatch-repair proficient (pMMR) colorectal cancer, a cohort historically resistant to immune checkpoint inhibitors. The session explores the molecular rationale behind current resistance and reviews emerging strategies to sensitize pMMR tumors to immunotherapy. Through clinical data and research insights, the lecture highlights potential combination therapies and innovative approaches to improve patient outcomes in this challenging patient population.
With GSK
Published
Aug 2026
Leading international experts explore the clinical relevance of MSI-H and MSS molecular signatures and their impact on surgical decision-making in colorectal cancer. Featuring multidisciplinary perspectives and a moderated panel discussion.
With GSK
Published
Jun 2026
Help your network discover Dr. Eric Christenson's clinical expertise.
